# 哺乳动物细胞银行市场 > 哺乳动物细胞库市场研究报告，按应用（药物开发、疫苗生产、基因治疗、单克隆抗体生产）、按细胞类型（附着细胞、悬浮细胞、干细胞）、按产品类型（母细胞库、工作细胞库）、按存储类型（液氮、控制速率冷冻、快速冷冻）以及按地区（北美、欧洲、南美、亚太、中东和非洲）- 预测到2035年 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.97% - **2024:** $ 7.49 Billion - **2025:** $ 8.01 Billion - **2035:** $ 15.72 Billion - **Key Players:** Thermo Fisher Scientific (US), Merck KGaA (DE), Lonza Group (CH), Sartorius AG (DE), Charles River Laboratories (US), WuXi AppTec (CN), Fujifilm Diosynth Biotechnologies (GB), Celerion (US), Eppendorf AG (DE) **Report ID:** MRFR/LS/37229-HCR · **Pages:** 128 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** September 17, 2026 **URL:** https://www.marketresearchfuture.com/reports/mammalian-cell-banking-market-39224 --- ## Market Summary ## **Mammalian Cell Banking Market Overview** As per MRFR analysis, the Mammalian Cell Banking Market Size was estimated at 7.49 (USD Billion) in 2024. The Mammalian Cell Banking Market Industry is expected to grow from 8.01 (USD Billion) in 2025 to 14.70 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 6.97% during the forecast period (2025 - 2034). ## **Key Mammalian Cell Banking Market Trends Highlighted** The Mammalian Cell Banking Market is experiencing significant growth, driven by the increasing demand for biopharmaceuticals and advanced therapies. The need for reliable cell lines to develop and produce biologics is pushing the market forward. Additionally, the rise of personalized medicine is encouraging the use of mammalian cells in research and therapeutic applications. The growing focus on biomanufacturing processes that require high-quality cell banks further supports this trend. There are numerous opportunities to be explored as the industry continues to evolve. The advancement in cell line development technologies presents a chance for market players to innovate their existing processes.Moreover, the expansion of biopharmaceutical companies in emerging markets can create a larger customer base. As regulatory agencies emphasize the importance of consistent product quality, companies can invest in developing and maintaining robust cell banking systems that comply with regulations. This creates a pathway for businesses to differentiate themselves in a competitive landscape. Recent trends show an increase in collaboration between research institutions and commercial entities aimed at optimizing cell line development. There is a growing interest in using CRISPR and other gene-editing technologies to enhance cell lines, which reflects the broader scientific advancements in the field.The emphasis on automation and digitalization in biomanufacturing is also noteworthy, as it leads to improved efficiency and reduced costs. Companies are expected to adapt to these shifts, ensuring that they remain at the forefront of technological advancements in mammalian cell banking. The alignment of research and manufacturing capabilities will be essential for long-term success in this growing market. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Mammalian Cell Banking Market Drivers** Growing Biopharmaceuticals Sector The Mammalian Cell Banking Market is rapidly expanding owing to the growth of the biopharmaceuticals market. There has been a surge of demand for therapies from biologics, especially those based on mammalian cells, as new technologies in the area of biotechnology become more sophisticated. The ability of these cell lines to produce complex proteins that are post-translationally modified to resemble human proteins makes them indispensable in the production of biopharmaceutical products, such as monoclonal antibodies, recombinant proteins and vaccines.The biopharmaceutical industry's reliance on mammalian cells for the production of biologics enhances the Mammalian Cell Banking Market, promoting the establishment of cell banks that ensure consistent cell line identity, quality and availability. Furthermore, stringent regulatory requirements necessitate the establishment of reliable cell banking systems, thereby driving the market's growth. As the global population increases and the prevalence of chronic diseases rises, the demand for effective and quality therapies continues to climb, thereby pushing investment and innovation in the mammalian cell banking sector.This upward trajectory supports the overall growth of the Mammalian Cell Banking Market industry, positioning it as a crucial component of the biopharmaceutical ecosystem. Technological Advancements in Cell Banking Technological advancements in cell banking processes are a vital driver for the Mammalian Cell Banking Market industry. Innovations in cryopreservation techniques, cell line characterization methodologies, and automated storage solutions enhance the efficiency and reliability of cell banking operations. These advancements not only improve the viability and longevity of preserved cells but also streamline workflows in laboratories and production facilities.With precise and robust cell banking systems, researchers and manufacturers can have higher confidence in the quality and consistency of their biological products. Furthermore, improvements in data management and tracking systems also facilitate better compliance with regulatory standards, contributing to the overall trust in mammalian cell lines within the industry. Increasing Research and Development Investments The rise in research and development investments across the life sciences sector is a significant driver impacting the Mammalian Cell Banking Market industry. As organizations invest heavily in R to explore new therapeutic opportunities, the need for reliable mammalian cell lines becomes paramount. Funding for research projects often focuses on innovative drug development, which increasingly relies on mammalian cells due to their ability to mimic human biology.Additionally, various research institutions and pharmaceutical companies are pursuing collaborations and public-private partnerships, further fueling the demand for effective cell banking solutions. This increased activity within R not only supports the establishment of cell banks but also places greater emphasis on quality-assured sources of mammalian cells, which is expected to further boost the market in the coming years. ## **Mammalian Cell Banking Market Segment Insights** **Mammalian Cell Banking Market Application Insights** The Mammalian Cell Banking Market, particularly in relation to application, showcases a robust valuation structure characterized by its primary focus on Drug Development, Vaccine Production, Gene Therapy and Monoclonal Antibody Production. By 2023, the market revenue will stand at approximately 6.55 USD billion, reflecting a growing interest in biopharmaceutical advancements. Among these applications, Drug Development holds a majority share, valued at 2.5 USD billion in 2023 and projected to reach 4.5 USD billion by 2032. This strong positioning highlights the critical role of mammalian cells in the therapeutic discovery process, serving as a foundation for more innovative and effective drug formulations. Vaccine Production represents another significant arena within the Mammalian Cell Banking Market, with a valuation of 1.5 USD billion in 2023, expected to increase to 2.75 USD billion by 2032. The evolving demand for vaccines, especially accentuated by recent global health challenges, underscores the importance of secure and reliable cell banking solutions to facilitate rapid and efficient vaccine generation. The Gene Therapy application, valued at 1.2 USD billion in 2023 and anticipated to rise to 2.25 USD billion by 2032, reflects the increasing emphasis on personalized medicine and targeted treatments. As gene therapy continues to expand its horizons, the role of mammalian cell banks in developing safe and effective gene therapies cannot be underestimated, representing a significant push towards cutting-edge healthcare solutions. Monoclonal Antibody Production, holding a value of 1.35 USD billion in 2023 and projected to reach 2.5 USD billion by 2032, also highlights a critical segment of the market. Monoclonal antibodies are pivotal in treating various diseases, including cancers and autoimmune disorders, thus showcasing the high demand for mammalian cell bank capabilities in producing these specialized drugs. The overall Mammalian Cell Banking Market data indicates consistent growth across its varied applications, bolstered by increasing biopharmaceutical research, technological advancements, and an ever-evolving understanding of genetic engineering. However, challenges such as high operational costs and stringent regulatory requirements persist, posing hurdles for market participants. Conversely, burgeoning opportunities in regenerative medicine and personalized healthcare practices present a hopeful trajectory for stakeholders within this dynamic industry. With an encouraging CAGR of 6.97 from 2024 to 2032, the Mammalian Cell Banking Market is set for further development, driven by the fusion of innovative technologies and a robust global healthcare approach. The strong emphasis on cellular banking solutions across these application areas reasserts their importance to advancing therapeutic modalities and securing the future of biopharmaceuticals. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Mammalian Cell Banking Market Cell Type Insights** The market segmentation on Cell Type focuses on Adherent Cells, Suspension Cells and Stem Cells. Adherent Cells are crucial due to their significant role in vaccine production and therapeutic protein manufacturing, often accounting for a considerable portion of the market share. Suspension Cells, on the other hand, dominate in large-scale processes, offering efficiency and scalability, making them vital for industrial applications.Stem Cells represent a rapidly growing segment, driven by advances in regenerative medicine and cell therapies, underlining their significance in fertile research avenues. The diverse application potential across these cell types significantly contributes to the overall market growth, aligned with the increasing demand for innovative therapeutic solutions. The trends show that the market is propelled by a rising number of biopharmaceutical firms and an increasing focus on personalized medicine, leading to more extensive use of mammalian cell banking.Overall, the Mammalian Cell Banking Market data and statistics underscore the crucial role that different cell types play in shaping the industry's future. **Mammalian Cell Banking Market Product Type Insights** The Mammalian Cell Banking Market has been showcasing significant growth driven by the increasing demand for biopharmaceuticals and advancements in cell-based technologies. Within the market, the classification into Product Type highlights key components like Master Cell Banks and Working Cell Banks, both crucial for ensuring the viability and reliability of cell lines used in production processes.Master Cell Banks play an essential role in maintaining the genetic stability and operational integrity of cell lines, often holding a majority presence within the industry. Meanwhile, Working Cell Banks, which are derived from Master Cell Banks and used for day-to-day production, also hold significant importance as they directly impact the efficiency of bioproduction. The demand for these products is propelled by their critical applications in vaccine production, monoclonal antibody development, and other therapeutic formulations, resulting in growing opportunities for market players.Overall, the Mammalian Cell Banking Market revenue portrays an evolving landscape with the potential to enhance bioprocess efficiencies and product quality. **Mammalian Cell Banking Market Storage Type Insights** Within this segment, storage methods such as Liquid Nitrogen, Controlled Rate Freezers, and Flash Freezing contribute significantly to the overall market data. Liquid Nitrogen, known for providing ultra-low temperatures essential for long-term preservation, holds a major share in the market due to its effectiveness in maintaining cell viability.Controlled Rate Freezing is also vital, often employed for its precision in cooling and preventing ice crystal formation, which can damage cells, thus ensuring high recovery rates upon thawing. Additionally, Flash Freezing is praised for its rapid cooling capabilities, making it a preferred choice for preserving sensitive cell lines. The Mammalian Cell Banking Market statistics indicate that these storage methods are driving market growth, aligning with the increasing demand for biopharmaceuticals and advancements in cell-based therapies.Nevertheless, challenges in storage cost and equipment maintenance remain, presenting both hurdles and opportunities for innovation in the industry. **Mammalian Cell Banking Market Regional Insights** North America holds a substantial position, with a valuation of 2.55 USD Billion in 2023, which reflects its majority holding in the industry due to advanced research facilities and high investments in biopharmaceuticals. Europe follows with a significant value of 1.75 USD Billion, driven by stringent regulatory frameworks that support cell banking services. The APAC region stands at 1.5 USD Billion, showing promise in terms of growth opportunities as countries enhance their biotechnology sectors.South America, albeit smaller, has a valuation of 0.5 USD Billion, indicating potential for development as the demand for innovative therapies increases. Lastly, the MEA region, valued at 0.25 USD Billion, represents a burgeoning market as healthcare infrastructure improves. Collectively, these regional insights reflect the Mammalian Cell Banking Market data, highlighting its segmentation and growth drivers across various territories. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Mammalian Cell Banking Market Key Players and Competitive Insights** The Mammalian Cell Banking Market is experiencing significant growth, fueled by advancements in biopharmaceuticals, personalized medicine, and tissue engineering. This market is characterized by the increasing demand for high-quality cell lines that can be used in the production of therapeutic proteins, vaccines, and monoclonal antibodies. As the industry progresses, the competitive landscape becomes increasingly dynamic, with companies leveraging innovative technologies and comprehensive service offerings to meet various regulatory compliance and quality standards. Strategic partnerships, mergers, and acquisitions also play a vital role in enhancing the capabilities and market share of key players, creating a vibrant ecosystem focused on addressing the challenges associated with cell banking processes, including collection, preservation, and quality control.Thermo Fisher Scientific stands out in the Mammalian Cell Banking Market due to its extensive portfolio of high-quality cell banking solutions and its commitment to delivering exceptional products and services. The company has established a robust presence through state-of-the-art facilities and a comprehensive approach towards customer support, ensuring that researchers and manufacturers have access to superior services throughout the entire cell banking process. Thermo Fisher Scientific’s strengths lie in its ability to provide customizable solutions tailored to specific client needs, along with its reputation for reliability and expertise in cell culture technologies. The organization focuses on maintaining stringent quality control standards, which reinforce customer confidence in its offerings, making it a preferred partner for companies needing mammalian cell lines for production purposes.Fujifilm Irvine Scientific holds a significant position in the Mammalian Cell Banking Market, recognized for its innovative approaches in cell culture media and related products. The company has cultivated a strong reputation for high-performance cell culture systems that are essential in developing mammalian cell banks. Fujifilm Irvine Scientific emphasizes research and development to continuously advance its product offerings, ensuring that they meet the evolving demands of the biopharmaceutical sector. With a focus on scientific expertise and customer collaboration, the company provides tailored solutions that enhance cell viability and productivity, thus reinforcing its standing in a competitive landscape. Moreover, Fujifilm Irvine Scientific's commitment to regulatory compliance and stringent quality assurance further solidifies its influence within the market, positioning it as a reliable partner for organizations looking to streamline their cell banking processes. ### **Key Companies in the Mammalian Cell Banking Market Include** **Mammalian Cell Banking Market Industry Developments** Recent developments in the Mammalian Cell Banking Market have been marked by significant growth and activity among key players. Companies such as Thermo Fisher Scientific and Merck KGaA continue to advance their cell banking technologies to support biomanufacturing processes. Furthermore, Wuxi Apptec and Catalent have expanded their service offerings in response to increasing demand for cell-based therapies and biologics production, reflecting a broader trend toward innovation in this sector. Recent reports indicate that Bristol-Myers Squibb has made strategic investments to enhance its cell banking capabilities, which are expected to accelerate drug development pipelines. In terms of mergers and acquisitions, it has been noted that Sartorius AG announced its acquisition of selected assets from software company WERS, which complements its cell banking solutions portfolio. Additionally, GE Healthcare's collaboration with ProBioGen signifies a pursuit of advanced cell culture technologies to better serve their clientele. Overall, these developments underscore dynamics in the mammalian cell banking sector, where companies are refining their strategies to meet ever-evolving market demands while enhancing production efficiencies. ## **Mammalian Cell Banking Market Segmentation Insights** **Mammalian Cell Banking Market Application Outlook** **Mammalian Cell Banking Market Cell Type Outlook** **Mammalian Cell Banking Market Product Type Outlook** **Mammalian Cell Banking Market Storage Type Outlook** **Mammalian Cell Banking Market Regional Outlook** -   -   -   -   -   - Beta Beta feature -   -   -   -   -   - Beta Beta feature ## Market Drivers ### 生物制药需求上升 生物制药的需求不断增加是哺乳动物细胞库市场的主要驱动力。随着医疗行业的不断发展，生物制剂的趋势日益明显，这些生物制剂源自活生物体。近年来，生物制药约占整个制药市场的25%。因此，对哺乳动物细胞系的需求预计将上升，这些细胞系对于生产这些生物制剂至关重要。此外，慢性疾病的日益普遍需要开发创新疗法，进一步推动了对哺乳动物细胞库解决方案的需求。因此，各公司正越来越多地投资于建立强大的细胞库，以确保为研究和生产提供高质量细胞的稳定供应。 ### 日益关注个性化医疗 个性化医疗的转变正在成为哺乳动物细胞银行市场的重要驱动力。随着医疗服务越来越多地针对个体患者的需求，特定细胞系的需求也在增加，这些细胞系可用于个性化治疗。这一趋势在专注于个性化治疗的临床试验数量不断增长中得到了体现，近年来增长超过30%。哺乳动物细胞银行在这一范式转变中发挥着至关重要的作用，因为它们提供了开发定制疗法所需的细胞系。此外，创建患者特异性细胞系的能力增强了治疗的有效性，从而推动了对先进细胞银行解决方案的需求。随着个性化医疗的持续发展，哺乳动物细胞银行市场可能会经历显著增长，推动这一增长的是对定制治疗选择的需求。 ### 细胞培养技术的进展 细胞培养方法中的技术创新正在显著影响哺乳动物细胞库市场。先进的生物反应器和自动化系统的引入提高了细胞培养过程的效率和可扩展性。例如，使用灌流系统可以实现连续细胞培养，从而提高所需产品的产量。此外，人工智能和机器学习在细胞培养优化中的整合变得越来越普遍，使研究人员能够以更少的试错获得更好的结果。这些进步不仅提高了哺乳动物细胞库的质量，还降低了生产成本，使公司更容易投资于细胞库解决方案。因此，市场可能会见证对支持哺乳动物细胞库行业增长的创新细胞培养技术的需求激增。 ### 细胞治疗的监管支持 监管机构越来越认识到基于细胞的疗法的重要性，这对哺乳动物细胞银行市场产生了积极影响。明确的指导方针和框架的建立促进了这一领域的创新。监管机构正在努力简化细胞疗法的审批流程，这鼓励公司投资于哺乳动物细胞银行解决方案。例如，针对再生医学产品的快速通道的引入使开发者更容易将其疗法推向市场。这种支持性的监管环境可能会增强对哺乳动物细胞库的需求，因为公司寻求确保符合严格的质量标准。随着基于细胞的疗法不断发展，哺乳动物细胞银行市场预计将从这些监管进展中受益。 ### 增加对生物技术的投资 生物技术领域投资的激增是哺乳动物细胞库市场的重要驱动力。风险投资资金和政府补助不断增加，生物技术公司获得了大量资金支持，以开发新疗法和产品。近年来，生物技术的投资达到了前所未有的水平，估计该行业吸引了超过500亿美元的资金。这一资本的涌入促进了新哺乳动物细胞库的建立，这对于生物制品和其他治疗剂的生产至关重要。此外，随着越来越多的初创企业在生物技术领域涌现，对可靠的细胞银行解决方案的需求预计将进一步增长，推动市场向前发展。对生物技术研究和开发的日益关注可能会为哺乳动物细胞银行行业创造一个有利的环境。 ## Future Outlook 哺乳动物细胞库市场预计将在2024年至2035年间以6.97%的年均增长率增长，推动因素包括生物制药的进步、对细胞治疗的需求增加以及监管支持。 **New opportunities:** - 开发自动化细胞培养系统以增强可扩展性。 进入新兴市场，提供量身定制的细胞银行解决方案。 与生物技术公司合作，开发创新的细胞系。 到2035年，哺乳动物细胞银行市场预计将会强劲增长，受到创新和战略合作伙伴关系的推动。 ## Segment Insights ### 按应用：单克隆抗体生产（最大）与基因治疗（增长最快） 哺乳动物细胞库市场展现出多样化的应用，其中单克隆抗体生产占据了最大的市场份额。该细分市场受益于对单克隆抗体在治疗干预中日益增长的需求，从而实现了显著的市场渗透。相反，基因治疗虽然目前是一个较小的细分市场，但随着基因工程的进步和基因治疗批准的增加，其增长速度迅猛，反映了生物制药领域不断演变的格局。哺乳动物细胞库在疫苗生产和药物开发中的应用完善了这一生态系统，每个部分都对市场的整体动态做出了贡献。 单克隆抗体生产（主导）与基因治疗（新兴） 单克隆抗体生产在哺乳动物细胞库市场中占据主导地位，主要由于其在治疗多种疾病（包括癌症和自身免疫疾病）中的广泛应用。它在很大程度上依赖于强大而高效的细胞系开发，以确保高产量和一致性。另一方面，基因治疗作为一种开创性力量正在崛起，利用创新技术提供针对性的治疗方案。其在CRISPR和基因编辑等技术方面的快速进展正在促进更多临床试验和批准。随着市场向个性化医疗转变，这两个领域有望相辅相成，单克隆抗体生产设定了高标准，而基因治疗则推动未来的增长。 ### 按细胞类型：附着细胞（最大）与悬浮细胞（生长最快） 在哺乳动物细胞银行市场中，细胞类型细分主要由附着细胞主导，这些细胞在研究和生产应用中已建立了显著的存在。它们的稳健和可靠特性使其成为各种疗法的首选，从而对该细分市场的整体市场份额做出了重要贡献。虽然附着细胞处于领先地位，但悬浮细胞正在蓬勃发展，由于其在大规模生产过程中的可扩展性和效率优势，正在获得越来越多的关注。 附着细胞（主导）与悬浮细胞（新兴） 附着细胞是哺乳动物细胞银行市场的重要组成部分，以其在表面或基材上生长的能力而受到认可，使其在众多生物制药应用中理想。它们允许更好的营养吸收和细胞相互作用，促进高质量治疗蛋白的生产。相比之下，悬浮细胞在该市场中呈现出一种新兴机会，其特点是在液体培养中自由移动，促进更高密度的生长和更快的发展周期。这种生长行为导致更低的成本和更高的生物加工生产力，使它们成为希望在细胞银行领域创新和提高效率的公司的有吸引力的选择。 ### 按产品类型：母细胞库（最大）与工作细胞库（增长最快） 在哺乳动物细胞银行市场中，母细胞库（MCB）占据了重要份额，因其在治疗蛋白质和其他生物制剂生产中的关键作用而成为最大的细分市场。MCB对于确保制造过程中使用的细胞系的一致性和质量至关重要，这也使其占据主导地位。另一方面，工作细胞库（WCB）作为MCB的必要补充，正在获得越来越多的关注，为扩大生产过程提供现成的细胞。它们的高效性和缩短处理时间的能力对生物制药公司越来越具吸引力。 产品类型：主细胞库（主导）与工作细胞库（新兴） 主细胞库（MCB）是一个高质量的细胞系集合，在严格控制的条件下维护，确保其在较长时间内的生存能力和遗传稳定性。这种环境使制造商能够持续生产大量生物制品。MCB细分市场目前主导市场，因为它对各种疾病指征的治疗开发至关重要。相反，工作细胞库（WCB）作为MCB的延伸，提供现成的细胞培养，促进更快的生产周转时间。由于对个性化疗法和生物技术创新的需求不断增加，这一细分市场正在迅速崛起，推动制造商采用WCB以满足生产目标，同时保持质量和合规性。 ### 按存储类型：液氮（最大）与控温速冻机（增长最快） 在哺乳动物细胞银行市场中，液氮仍然是主导的存储类型，因其在维持哺乳动物细胞的活性方面的有效性而占据最大的市场份额。液氮能够将细胞保持在超低温下，这对于长期存储至关重要，使其成为许多生物制药公司的首选。相比之下，受益于技术进步，控制速率冷冻机正在迅速获得关注，这些技术允许在冷冻过程中进行精确的温度控制。这确保了细胞的完整性和活性，满足了对高质量细胞银行解决方案日益增长的需求。 液氮（主导）与控制速率冷冻机（新兴） 液氮因其无与伦比的冷却能力和在数十年内保持细胞完整性的有效性，巩固了其在哺乳动物细胞银行市场中的主导存储方法的地位。它在实验室和生物制药公司中的广泛应用凸显了其可靠性和成本效益。同时，受控速冻机作为一个重要参与者正在崛起，创新技术使得能够控制冷冻速率，从而最小化细胞压力和损伤。这个不断增长的细分市场吸引了关注高细胞活力和解冻后活力率的组织，因此成为尖端细胞治疗和再生医学应用的一个重要选择。 ## Regional Market Share Analysis ### 北美：创新与领导中心 北美是哺乳动物细胞银行最大的市场，占全球市场份额的约45%。该地区受益于先进的研究设施、对生物技术的重大投资以及鼓励创新的强大监管框架。对生物制药和个性化医疗的日益需求推动了增长，同时政府的支持性举措旨在改善医疗保健结果。美国在市场中处于领先地位，主要参与者如赛默飞世尔科技和查尔斯河实验室推动了竞争。加拿大也发挥了重要作用，为该地区的增长做出了贡献。成熟公司的存在和对研发的强烈关注创造了一个促进创新与合作的竞争环境，确保北美在哺乳动物细胞银行领域的持续领导地位。 ### 欧洲：新兴生物技术强国 欧洲是哺乳动物细胞银行的第二大市场，占全球市场份额的约30%。该地区以对研究和开发的强烈重视为特征，得到了各种政府倡议和资金计划的支持，旨在增强生物制药生产。监管框架，如欧洲药品管理局的指导方针，在塑造市场动态和确保遵守安全标准方面至关重要。德国、英国和法国是该领域的领先国家，默克KGaA和萨托里乌斯AG等公司发挥了关键作用。竞争环境以学术机构与行业参与者之间的合作为特征，促进了创新。众多生物技术公司的存在和对基于细胞的疗法日益关注进一步增强了欧洲在哺乳动物细胞银行市场的地位。 ### 亚太地区：快速增长的市场 亚太地区的哺乳动物细胞银行市场正在迅速增长，占全球市场份额的约20%。该地区的扩张受到对生物技术的投资增加、医疗保健支出的上升以及对生物制药日益关注的推动。中国和印度等国正在崛起为关键参与者，得到了有利的政府政策和蓬勃发展的医疗保健行业的支持，后者需要先进的细胞银行解决方案。中国是该地区最大的市场，吴晓波AppTec等公司做出了重要贡献。印度也在获得关注，越来越多的生物技术初创公司进入市场。竞争环境正在演变，本地和国际参与者争夺市场份额，导致细胞银行技术和服务的创新。 ### 中东和非洲：未开发的潜力市场 中东和非洲（MEA）地区在哺乳动物细胞银行市场中逐渐崭露头角，目前占全球市场份额的约5%。增长主要受到对医疗保健基础设施投资增加和对生物制药需求上升的推动。该地区的政府正在实施政策以增强医疗服务，预计这将在未来几年催化市场增长。南非和阿联酋等国正在引领潮流，越来越多的生物技术公司和研究机构正在涌现。竞争环境仍在发展中，本地和国际参与者都有机会建立立足点。随着该地区继续投资于生物技术，哺乳动物细胞银行市场的增长潜力显著，为未来的进步铺平了道路。 ## Competitive Benchmarking 哺乳动物细胞银行市场的特点是动态的竞争格局，受到生物制药需求增加和细胞培养技术进步的推动。像赛默飞世尔科技（美国）、默克KGaA（德国）和隆泽集团（瑞士）等主要参与者在战略上定位，以利用其广泛的产品组合和技术能力。这些公司专注于创新和合作伙伴关系，以增强其服务产品，从而塑造一个强调细胞银行解决方案质量和可靠性的竞争环境。 在商业策略方面，公司越来越多地本地化制造和优化供应链，以有效满足区域需求。市场看起来适度分散，几家主要参与者在各个细分市场上施加影响。这种分散使得小型参与者能够蓬勃发展，而大型公司则通过战略收购和合作巩固其市场地位。 2025年8月，赛默飞世尔科技（美国）宣布扩建其在马萨诸塞州的细胞培养基生产设施。这一战略举措可能会增强其满足对高质量细胞培养产品日益增长的需求的能力，从而巩固其市场领导地位。该扩建与公司对创新和运营卓越的承诺相一致，使其在竞争对手面前处于有利地位。 2025年9月，默克KGaA（德国）推出了一条新的细胞银行服务线，旨在加速细胞治疗的开发。这一举措强调了默克对创新的关注及其意图在生物制药市场中占据更大份额。通过提供量身定制的细胞银行解决方案，默克可能会增强其竞争优势并吸引更广泛的客户群。 2025年7月，隆泽集团（瑞士）与一家领先的生物技术公司达成战略合作伙伴关系，共同开发先进的细胞银行技术。这一合作表明隆泽的战略是将尖端技术整合到其产品中，可能增强其服务能力和市场覆盖范围。这种合作关系还可能促进知识共享和创新，进一步巩固隆泽在市场中的地位。 截至2025年10月，哺乳动物细胞银行市场的当前竞争趋势包括向数字化、可持续性和人工智能在运营过程中的整合的明显转变。战略联盟越来越多地塑造市场格局，使公司能够汇聚资源和专业知识。展望未来，竞争差异化预计将演变，更加重视创新和技术，而不仅仅是价格。优先考虑供应链可靠性和技术进步的公司可能会在这个快速发展的市场中脱颖而出。 ## Recent News & Developments 最近，哺乳动物细胞银行市场的发展标志着关键参与者之间的显著增长和活动。像赛默飞世尔科技和默克KGaA这样的公司继续推进其细胞银行技术，以支持生物制造过程。此外，药明康德和凯捷在响应对细胞治疗和生物制品生产日益增长的需求方面扩大了其服务产品，反映出该行业创新的更广泛趋势。最近的报告显示，百时美施贵宝已进行战略投资，以增强其细胞银行能力，这预计将加速药物开发管道。 在并购方面，萨托里乌斯公司宣布收购软件公司WERS的部分资产，这补充了其细胞银行解决方案组合。 此外，GE医疗与ProBioGen的合作标志着追求先进细胞培养技术，以更好地服务其客户。总体而言，这些发展突显了哺乳动物细胞银行行业的动态，各公司正在完善其战略，以满足不断变化的市场需求，同时提高生产效率。 ## Report Scope | 2024年市场规模 | 7491（亿美元） | | --- | --- | | 2025年市场规模 | 8014（亿美元） | | 2035年市场规模 | 1572（亿美元） | | 年复合增长率（CAGR） | 6.97%（2024 - 2035） | | 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 | | 基准年 | 2024 | | 市场预测期 | 2025 - 2035 | | 历史数据 | 2019 - 2024 | | 市场预测单位 | 亿美元 | | 关键公司简介 | 市场分析进行中 | | 覆盖的细分市场 | 市场细分分析进行中 | | 关键市场机会 | 细胞系开发技术的进步提高了哺乳动物细胞库市场的效率。 | | 关键市场动态 | 生物制药需求的上升推动了哺乳动物细胞库市场的创新和整合。 | | 覆盖的国家 | 北美、欧洲、亚太、南美、中东和非洲 | ## Frequently Asked Questions **Q: 哺乳动物细胞银行市场的当前估值是多少？** A: 截至2024年，哺乳动物细胞银行市场的估值为74.91亿美元。 **Q: 到2035年，哺乳动物细胞库市场的预计市场规模是多少？** A: 预计到2035年，市场估值将达到157.2亿美元。 **Q: 在预测期内，哺乳动物细胞银行市场的预期CAGR是多少？** A: 预计2025年至2035年哺乳动物细胞银行市场的年均增长率（CAGR）为6.97%。 **Q: 在哺乳动物细胞银行市场中，哪些应用领域正在推动增长？** A: 关键应用领域包括药物开发、疫苗生产、基因治疗和单克隆抗体生产，其中药物开发预计将从25亿美元增长到52亿美元。 **Q: 在哺乳动物细胞银行市场中，领先的公司有哪些？** A: 市场上的主要参与者包括赛默飞世尔科技、默克集团、隆泽集团和萨托里乌斯公司。 **Q: 不同细胞类型如何对哺乳动物细胞银行市场做出贡献？** A: 附着细胞、悬浮细胞和干细胞具有重要意义，预计干细胞将从29.91亿增长到62.2亿USD。 **Q: 哺乳动物细胞银行市场有哪些类型的产品？** A: 市场包括主细胞库和工作细胞库，预计将从37.455亿美元增长到78.6亿美元。 **Q: 在哺乳动物细胞银行市场中使用了哪些存储类型？** A: 存储类型包括液氮、控制速率冷冻机和快速冷冻，预计液氮将从29.96亿美元增长到62.5亿美元。 **Q: 哺乳动物细胞银行市场如何支持疫苗生产？** A: 疫苗生产是一个关键领域，预计将从15亿美金增长到32亿美金，反映出市场在生物制药开发中的作用。 **Q: 哪些趋势正在影响哺乳动物细胞银行市场？** A: 趋势包括细胞培养技术的进步和生物制药需求的增加，这可能会推动市场在2035年前的增长。 --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/mammalian-cell-banking-market-39224*